Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA033989 in Myeloproliferative Neoplasms
NCT05936359Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2023
- Primary completion
- Feb 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of inca033989 in myelofibrosis (MF) and essential thrombocythemia (ET) (7 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-emergent Adverse Events at 60 days and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
inca033989
03
Conditions
myelofibrosis (MF)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT05936359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936359.